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Obstructive sleep apnea is common among patients referred
for coronary artery bypass grafting and can be diagnosed by
portable monitoring
Naury de Jesus Danzi-Soaresa, Pedro Rodrigues Gentaa,
Fla´via Baggio Nerbassa, Rodrigo Pinto Pedrosaa, Fla´via Souza Nunes Soaresa,
Luis Antonio Machado Ce´sarb, Luciano F. Dragera, Robert Skomroc
and Geraldo Lorenzi-Filhoa
Background Obstructive sleep apnea (OSA) is common
among patients with coronary artery disease. However,
OSA remains largely under recognized. The lack of clinical
suspicion and difficulties to access full polysomnography
(PSG) are limiting factors. The aim of this study was to
evaluate, among patients referred to coronary artery
bypass grafting (CABG): (i) the prevalence of OSA, (ii)
the association of OSA with clinical symptoms, (iii) the
performance of overnight unattended portable monitoring
(PM) as an alternative method for the diagnosis of OSA.
Methods Consecutive patients referred for CABG were
evaluated by standard physical evaluation and validated
questionnaires (Berlin questionnaire and Epworth
Sleepiness Scale) and underwent full PSG and PM
(Stardust II).
Results We studied 70 consecutive patients (76% men),
age 58±7 years (mean±SD), BMI [median (interquartile
range)] 27.6 kg/m2 (25.8–31.1). The prevalence of OSA (full
PSG) using an apnea–hypopnea index of at least 5 events/h
was 87%. Commonly used clinical traits for the screening
of OSA such as the Epworth Sleepiness Scale and neck
circumference had low sensitivities to detect OSA. In
contrast, the Berlin questionnaire showed a good
sensitivity (72%) to detect OSA. PM showed good
sensitivity (92%) and specificity (67%) for the diagnosis
of OSA.
Conclusion OSA is strikingly common among patients
referred for CABG. The Berlin questionnaire, but not
symptom of excessive daytime sleepiness is a useful tool
to screen OSA. PM is useful for the diagnosis of OSA and
therefore is an attractive tool for widespread use among
patients with coronary artery disease. Coron Artery Dis
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Introduction
Obstructive sleep apnea (OSA) is characterized by
repeated episodes of partial or complete upper airway
obstruction during sleep, and is associated with recurrent
hypoxemia and arousals [1]. OSA is a public health problem
with a prevalence ranging from 4 to 25% in the general
population [2,3]. OSA is tightly linked to cardiovascular
disease, and the prevalence of OSA is much higher in
patients with established cardiovascular disease [4], such as
hypertension [5,6], atrial fibrillation [7], and hypertrophic
cardiomyopathy [8]. The estimated prevalence of OSA
among patients with coronary artery disease (CAD) ranges
from 40 to 45% [9–13]. Therefore, patients referred to
coronary artery bypass grafting (CABG) may present a high
prevalence of OSA. The recognition of OSA in patients
with CAD is important since OSA may be associated with
increased risk of acute myocardial infarction and stroke [4].
There is also evidence that OSA is independently
associated with postoperative complications [14–17].
Despite the potential importance, OSA remains largely
under-recognized among patients with established cardio-
vascular disease [4]. One potential limitation is the recent
evidence that several clinical characteristics typical of
patients with OSA may not be present in patients with
established cardiovascular disease. In contrast to patients
referred to sleep laboratories, OSA is not frequently
accompanied by excessive daytime sleepiness among
patients with hypertension [5], stroke [18], patients with
long-term pacing [19], and metabolic syndrome [20]. The
lack of typical symptoms may contribute to the low
recognition of OSA among patients with established
cardiovascular disease. A major limitation is the reduced
availability and the high costs of the gold standard method
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for OSA, full polysomnography (PSG) [1,21]. Portable
monitoring (PM) is a promising alternative for OSA
diagnosis [22]. PM is similar to a Holter monitor and
precludes the necessity of a sleep technician attending the
study. PM offers the advantage of being possible to be
applied in multiple settings such as hospital, coronary care
unit, intensive care unit, wards, as well as at home. PM has
been validated earlier for the diagnosis of OSA among
preselected populations referred to sleep laboratories
[23–25]. However, the use of PM among populations not
triaged by a sleep specialist remains unestablished.
The prevalence of OSA has not been systematically
evaluated among patients referred for CABG. We
reasoned that these patients undergo an extensive
preoperative evaluation and that this would be a window
of opportunity to recognize and establish OSA diagnosis.
The aim of this study was to determine among
consecutive patients referred to CABG: (i) the preva-
lence of OSA, (ii) the association with clinical symptoms
that may help the recognition of OSA, and (iii) the
performance of the type III PM device (Stardust II) for
OSA diagnosis.
Methods
Study design
All patients underwent a detailed clinical evaluation
including biochemical analysis and echocardiography
followed by a full PSG and PM on separate nights before
surgery. All patients first performed PSG and then PM, as
detailed below. All sleep studies were scored blindly by
an experienced technologist and interpreted by a sleep
medicine physician.
Participants
We studied consecutive patients with severe CAD, above
40 years of age referred for CABG and evaluated in a
single outpatient clinic at the Heart Institute (InCor),
University of Sa˜o Paulo Medical School, Sa˜o Paulo, Brazil.
We excluded patients with previous diagnosis of OSA,
history of stroke with severe disability, and patients with
clinical instability, defined as clinical admission for
decompensated heart failure or changes in medication
over the last month and patients on use of supplemental
oxygen. All procedures were carried out in accordance
with institutional guidelines. The protocol was approved
by the System of Scientific Documentation and Com-
mittee of Analysis of Research Projects, from the Clinics
Hospital, University of Sa˜o Paulo Medical School
(number 168/06) and a written informed consent was
obtained from all participants.
Clinical evaluation
In the preoperative period, all participants underwent
a detailed history and physical examination, including
measurement of blood pressure, abdominal and neck
circumferences. Large neck circumference (Z 43.2 and
Z 40.6 cm, for men and women) was suggestive of OSA as
described earlier [26]. The Berlin questionnaire and the
Epworth Sleepiness Scale were used to evaluate clinical
signs and symptoms suggestive of OSA.
Berlin questionnaire
The Berlin questionnaire classifies patients as having
a low or high risk for OSA. The classification is based
on responses in three symptom categories concerning
snoring, tiredness, and the presence of comorbidities.
Briefly, being positive in category 1 is defined as
persistent symptoms (> 3–4 times/weeks) in two or
more questions about snoring. Category 2 is defined as
positive by the presence of persistent tiredness (> 3–4
times/weeks). Category 3 is defined as positive by the
presence of hypertension or a BMI of at least 30 kg/m2. To
be considered at high risk for OSA, a patient has to be
positive in at least two symptom categories [27].
Epworth Sleepiness Scale
The Epworth Sleepiness Scale was used to evaluate
subjective excessive daytime sleepiness. Briefly, the
patient rates the probability of dozing of 0–3 in eight dif-
ferent conditions, and a score above 10 points represents
the presence of excessive daytime sleepiness [28].
Laboratory evaluation
Blood samples were drawn for determination of fasting
glucose, total cholesterol, low-density lipoprotein, high-
density lipoprotein, triglycerides, and creatinine. Two-
dimensional echocardiography with M-mode recording
was obtained according to the American Society of
Echocardiography [29]. Systolic dysfunction was defined
by a left ventricular ejection fraction of 45% or less.
Polysomnography
The standard PSG performed in the sleep laboratory
overnight included electroencephalography (C3/A2,C4/
A1,O1/A2,O2/A1), electrooculography, submental and ante-
rior tibialis electromyography, pulse oximetry, measure-
ments of airflow thermistor and nasal pressure, body
position detector, snoring sounds detector, and measure-
ments of rib cage and abdominal movements during
breathing (XactTrace, EMBLA Medical Devices, Broom-
field, Colorado, USA). Sleep stages were scored according
to the criteria proposed by Rechtschaffen and Kales [30].
Hypopnea was defined as a 50% in airflow lasting at least
10 s associated with oxygen desaturation of greater than 3%
or with an arousal. Apnea was defined when cessation of
airflow lasted at least 10 s and was further classified based
on presence or absence of respiratory effort as central,
obstructive, or mixed [31]. The apnea–hypopnea index
(AHI) was calculated as the total number of respiratory
events per hour of sleep. The classification of severity of
OSA was defined according to AHI as mild (5–14.9),
moderate (15–29.9), and severe (Z 30 events/h) [1].
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Portable monitoring
All participants underwent an overnight study with a
standard four-channel recording device (Stardust II,
Respironics Inc., Murrysville, Pennsylvania, USA). This
device records nasal pressure, thoracic excursion (as
measured by a piezoelectric crystal), body position, pulse
oximetry, heart rate, and is classified as type 3 in
accordance with the AASM recommendations [25]. PM
sleep studies were unattended and performed on the
ward, in the preoperative period 2–3 days before surgery.
Hypopnea was defined as a 50% or discernible decrement
in airflow lasting at least 10 s with a 3% reduction in
oxygen saturation. Apnea was defined when cessation of
airflow lasted at least 10 s and was further classified
as central, obstructive, or mixed based on presence of
respiratory effort [31]. The total recording time was used
as the denominator to calculate the AHI [1].
Statistical analysis
Data were analyzed with SPSS 17.0 (SPSS Inc., Chicago,
Illinois, USA) statistical software. The sample size was
determined according to previous studies [32,33]. Assum-
ing a SD of 9 on AHI and the minimum important
difference in AHI of 5 to obtain a power of 90% and an a of
0.05, 69 participants were required. After checking normal-
ity with the Kolmogorov–Smirnov test, the results were
expressed as mean±SD, median (interquartile range), or
in percentages, when appropriate. Wilcoxon signed-rank
test and paired Student t-test or Mann–Whitney U-tests
were used for independent samples and w2-tests were used
to compare frequency variables between patients without
and with OSA. Sensitivity, specificity, positive likelihood
ratio, and negative likelihood ratio and the negative and
positive predictive values for each AHI cut-off value of 5
and 15 events/h were calculated using the AHI value from
PSG and PM. Bland–Altman plots was generated to assess
agreement between the PSG and PM results [34]. Receiver
operator curves (ROC curves) were constructed to
illustrate true-positive and false-positive results with AHI
cut-off values of 5 and 15 events/h. We also analyzed the
agreement between PSG and PM as described ear-
lier [32,33]. Briefly, diagnostic agreement was considered
when AHI was at least 30 events/h on both systems or, if
AHI less than 30 events/h on PSG, the AHI was within 10
events/h on both systems. Overestimate of AHI by PM was
defined as AHI 10 events/h greater on PM than PSG (both
less than 30 events/h). Underestimation of AHI by PM was
defined as AHI 10 events/h less on PM than PSG (both
<30 events/h) [32,33]. A P value of 0.05 or less was
considered statistically significant.
Results
We prospectively enrolled 79 patients referred for CABG.
Four patients withdrew from the study (two withdrew
consent, one presented clinical instability and one CABG
cancelled). Five patients were further excluded because
of technical problems, one being full PSG (computer
malfunction) and four PM (two lost oximetry signal, one
patient lost the canulla signal and one study had the data
corrupted during the download process). Therefore, 70
patients (53 men, 17 women) comprised the final sample
(Fig. 1). The median interval between PSG and PM
studies was [median (IQR)] 4 (2–36) days. All patients
were clinically stable and there were no changes in body
weight between PSG and PM studies, (77.3±15.7 and
77.4±15.8 kg, respectively, P=0.96). The population
studied consisted predominantly of middle age, over-
weight Caucasians. The baseline characteristics of the
entire population are presented in Table 1. Forty-two
patients had no previous history of myocardial infarction,
and only eight patients (11%) presented a recent acute
myocardial infarction (< 3 months). The number (per-
centage) of patients with AHI from 0–4.9, 5–14.9,
15–29.9, and Z 30 events/h as determined by full PSG
was 9 (12.9%), 23 (32.9%), 19 (27.1%), and 19 (27.1%),
respectively. Therefore, the prevalence of OSA consider-
ing an AHI of at least 5, at least 15 events/h was 87 and
54%, respectively. Table 2 shows respiratory events and
minimum oxygen saturation obtained during PSG and
PM. Despite statistical differences, the respiratory
variables were in the same range. The mean difference
in AHI between the two diagnostic methods (Bland–
Altman plot) was+5.3 events/h, indicating that AHI
values from PM were on average lower than those from
PSG. The SD of the difference was 14.6 events/h (Fig. 2).
The agreement between PM and PSG was 73%, with PM
underestimating AHI in 23% and overestimating in 4%
of cases.
The sensitivity, specificity, positive and negative pre-
dictive values of PM using the AHI cut-offs (Z 5 and
Z 15 events/h) are presented in Table 3. The sensitivity
diminished and the specificity increased in direct relation
to the increase in the AHI cut-off value. The correspond-
ing positive predictive value also decreased. The
performances of the clinical characteristics for identifica-
tion of the OSA AHI at least 5 events/h and moderate-to-
severe OSA (AHI at least 15 events) are described
in Table 4. ROC curves of different AIH cut-offs (Z 5
and Z 15 events/h) from PM are presented in Fig. 3. The
areas under the curve for each cut-off are 0.90 and 0.79,
respectively.
Discussion
This study systematically evaluated the presence of OSA
in a unique population of consecutive patients evaluated for
CABG and contributes to the literature by showing: (i) the
prevalence of OSA is strikingly high, and 54% present
moderate-to-severe OSA, (ii) several symptoms and traits
typical of OSA observed in patients referred to sleep
laboratories, such as excessive daytime sleepiness and large
neck circumference is inaccurate to identify OSA in this
population, (iii) PM is a useful tool for the diagnosis of OSA
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in this population. Taken together, our study suggests the
widespread use of PM in patients evaluated for CABG
given the high prevalence of OSA and the low specificity of
clinical symptoms.
OSA is now recognized as an independent risk factor for
several cardiovascular diseases, including hypertension,
atrial fibrillation, and mortality due to stroke and
CAD [4–7,10,13,35]. Among patients with established
cardiovascular disease the prevalence of OSA is strikingly
high. For instance, among patients with CAD, the
estimated prevalence of OSA ranges from 40 to
45% [9]. Despite all this evidence, the clinical suspicion
of OSA remains low and the vast majority of patients
referred to cardiology centers remains undiagnosed. The
reasons for this gap are multiple, and may include the lack
of typical symptoms and physical traits that are thought
to be present in patients with OSA. Supporting this
hypothesis, in this study, excessive daytime sleepiness
and large neck circumference showed low sensitivity
(Table 4). In contrast, the Berlin questionnaire that uses
a composite of three categories, including snoring,
presence of tiredness (and not excessive daytime
sleepiness) and presence of obesity or hypertension
presented a reasonable performance to detect OSA
(Table 4). Our results are in line with several studies
that evaluated consecutive patients with cardiovascular
disease, including patients with stroke [18], patients
referred for pace-maker implant [19], and consecutive
patients with metabolic syndrome [20] and hyperten-
sion [5]. Most of these studies showed little association
between OSA and typical symptoms such as excessive
daytime sleepiness. These findings may help to explain
the low clinical suspicion of OSA among patients seen in
the cardiovascular clinic outside the sleep community.
In the context of a population with high prevalence of
OSA in whom the clinical symptoms and physical traits
are not particularly helpful for the triage of the patients,
it is important to validate a simple test to detect OSA.
PM is recommended as an alternative method for OSA
diagnosis and has been validated against the gold standard
PSG. However, most validation studies were performed
among preselected patients referred to sleep centers
Fig. 1
Total patients screened (n=100)
Refused to participate (n=5)
Stroke with severe disability (n=7)
Lost to follow-up (n=4)
Refused PSG (n=5)
Withdrew consent (n=2)
Presented clinical instability (n=1)
CABG cancelled (n=1)
Excluded for technical problems (n=5)
Excluded patients (n=21)
Total enrolled patients (n=79)
Additional exclusions (n=4)
n=75 patients
n=70 patients
PSG (n=1) PM (n=4)
Patient recruitment flowchart. CABG, coronary artery bypass grafting; PN, portable monitor; PSG, polysomnography.
34 Coronary Artery Disease 2012, Vol 23 No 1
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
[23,24,32,33,36,37]. The recent clinical guidelines of the
American Association of Sleep Medicine recommend that
the use of PM should be restricted to patients with a high
pretest probability of moderate-to-severe OSA without
significant comorbid conditions [25]. Our study therefore
evaluated the performance of PM among patients that were
not evaluated and triaged by a sleep center, therefore
testing the performance of PM in a clinical cardiology
setting. There were several statistical differences when the
mean values of respiratory parameters derived from PM and
PSG (Table 2). However, the majority of the differences
were probably of little clinical significance and may be at
least in part explained by the night-to-night variability of
AHI [36,38] or possibly reflecting the differences between
equipment technologies, sampling rate, or analytical soft-
ware [32]. The Bland–Altman plot indicated a substantial
agreement between PM and PSG, particularly at low levels
of AHI (Fig. 2). The ROC curves (Fig. 3) also showed a
good performance of PM (area under the curve between
0.90 and 0.79) at all AHI cut-offs. Our study showed that
PM presented acceptable sensitivity to detect OSA and
acceptable specificity to exclude moderate-to-severe OSA
revealing therefore a good performance of PM (Table 3).
The use of PM in patients evaluated for CABG may be
of particular importance not only because of the high
prevalence, but also because of the potential clinical
importance of recognizing OSA in the preoperative
Table 1 Baseline characteristics of the study population
Total
n=70
No OSA (AHI < 15)
n=32
OSA (AHI Z15)
n=38 P value
Male (%) 53 (76) 21 (66) 32 (84) 0.07
Caucasians (%) 52 (74) 21 (66) 31 (82) 0.30
Age (years) 58±7 56±7 59±8 0.06
BMI (kg/m2) 27.6 (25.8–31.1) 27.1 (25.5–30.6) 28.0 (25.8–31.7) 0.23
Neck circumference (cm) 40.0 (37.4–42.0) 38.8 (35.9–40.5) 41.0 (38.9–42.6) 0.02*
Waist circumference (cm) 100.9±12.1 97.8 (90.3–106.5) 103.4 ±11.1 0.08
ESS 7 (5–11) 7 (4–11) 7 (5–10) 0.96
ESS >10, n (%) 17 (24) 9 (28) 8 (21) 0.44
High risk, Berlin, n (%) 49 (70) 21 (66) 28 (74) 0.46
Heart rate (beats/min) 68 (60–76) 67 (59–76) 69 (60–76) 0.71
Systolic blood pressure (mmHg) 130 (110–150) 130 (109–148) 130 (110–150) 0.73
Diastolic blood pressure (mmHg) 80 (70–84) 80 (67–80) 80 (70–87) 0.43
Comorbidities
Smoking (%) 12 (17) 5 (16) 7 (18) 0.86
Hypertension (%) 57 (81) 26 (81) 31 (82) 0.97
Diabetes mellitus (%) 28 (40) 12 (38) 16 (42) 0.70
Stroke (%) 7 (10) 3 (9) 4 (11) 0.87
Blood samples
Glucose (mg/dl) 105 (95–139) 105 (94–150) 104 (96–134) 0.95
Creatinine (mg/dl) 1.1 (0.9–1.2) 1.0 (0.9–1.2) 1.1 (0.9–1.3) 0.19
Total cholesterol (mg/dl) 177 (143–211) 180 (142–213) 176 (143–210) 0.71
LDL (mg/dl) 108 (85–127) 112 (83–129) 104 (85–131) 0.55
HDL (mg/dl) 37 (31–40) 36 (30–40) 37 (31–40) 1.0
Triglycerides (mg/dl) 143 (99–198) 148 (96–185) 138 (101–234) 0.58
Medications
Statins (%) 62 (89) 31 (97) 31 (82) 0.05
b-blockers (%) 65 (93) 30 (94) 35 (92) 0.79
ACEI/ARB (%) 53 (76) 23 (72) 30 (79) 0.49
ASA (%) 46 (66) 20 (63) 26 (68) 0.60
Diuretics (%) 25 (36) 14 (44) 11 (29) 0.20
Nitrate (%) 35 (50) 18 (56) 17 (45) 0.34
Calcium channel blockers (%) 25 (36) 10 (31) 15 (39) 0.47
Oral antidiabetics (%) 4 (6) 2 (6) 2 (5) 0.86
Insulin (%) 9 (13) 3 (9) 6 (16) 0.42
Echocardiography
Ejection fraction (%) 56 (44–65) 60 (45–66) 55 (40–65) 0.39
Ejection fraction r45%, n (%) 20 (29) 9 (28) 11 (29) 0.51
Values are mean ( ±SD). Variables with skewed distribution are presented as median (25–75% interquartile range) or percentage.
ACEI, angiotensin-converting enzyme inhibitor; AHI, apnea-hypopnoea index; ARB, angiotensin receptor blocker; ASA, acetylsalicylic acid; ESS, Epworth Sleepiness
Scale; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OSA, obstructive apnea.
*P<0.05.
Table 2 Comparison of respiratory parameters observed on
polysomnography and portable monitoring
PSG PM P value
Total recording time/min 451.6±40.9 423.0±60.7 <0.01*
Total sleep time/min 356.0±70.3 – –
AHI (events/h) 22.9±20.0 17.5±13.9 <0.01*
OA (events/h) 5.0±7.6 7.6±9.6 <0.01*
CA (events/h) 2.4±8.1 1.1 ±3.0 0.35
MA (events/h) 0.6±3.7 0.3 ±1.44 0.59
HI (events/h) 14.8±12.0 8.5 ±6.6 <0.01*
Mean Sp02% 94.3±2.0 94.0 ±2.2 0.37
Lowest Sp02% 85.0±7.0 81.8 ±8.3 <0.01*
Values are mean ( ±SD). Variables with skewed distribution are presented as
median (25–75%, interquartile range) or percentage.
AHI, apnea–hypopnoea index; CA, central apnea; HI, hypopnoea index; MA,
mixed apnea; OA, obstructive apnea; PM, portable monitoring; PSG, polysomno-
graphy; SpO2, oxygen saturation.
*P<0.05.
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period [14–17]. OSA can contribute to cardiovascular
disease by multiple mechanisms, including intermittent
hypoxemia, increase of the sympathetic activation with
surges in blood pressure, that in conjunction with
simultaneous changes in intrathoracic and cardiac trans-
mural pressures may trigger or contribute to cardiac
ischemia, arrhythmia, and CAD [4,7,9]. There is evidence
that OSA contributes independently to atherosclerosis
progression [39] that can be partially reverted with the
treatment of OSA with continuous positive airway
pressure [40]. Continuous positive airway pressure can
also reduce the appearance of new cardiovascular events
among patients with CAD [41], and reduce cardiovascular
mortality among patients referred to sleep studies [42].
There is also some evidence suggesting that patients with
OSA have a higher incidence of postoperative complica-
tions [14–17]. The use of PM in this population offers
potential advantages over PSG: easier access, no need to
transfer patients to another facility (many cardiology
wards do not have access to PSG), and lack of PSG
technical supervision may result in overall reduction of
health care costs in this population.
Fig. 2
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Bland–Altman plot of apnea–hypopnea index from polysomnography (PSG) and portable monitoring (PM).
Table 3 Sensitivity, specificity, positive predictive value and negative predictive value, positive likelihood ratio (LR+ ) and negative
likelihood ratio (LR– ) for different cut-offs of AHI from the polysomnography and portable monitoring
Sensitivity Specificity PPV NPV LR+ LR–
AHI Z5 events/h 0.92 (0.81–0.97) 0.67 (0.31–0.91) 0.95 (0.85–0.99) 0.54 (0.24–0.81) 2.75 (1.09–6.96) 0.12 (0.05–0.32)
AHI Z15 events/h 0.66 (0.49–0.80) 0.78 (0.60–0.90) 0.78 (0.60–0.90) 0.66 (0.49–0.80) 3.01 (1.50–6.02) 0.44 (0.28–0.69)
AHI, apnea–hypopnea index; NPV, negative predictive value; PPV, positive predictive value.
Table 4 Performances of the clinical characteristics for identification the OSA for AHI Z5 and AHI Z15 events/h
Sensitivity (%) Specificity (%) PPV (%) NPV (%) LR+ LR–
AHI Z5events/h
ESS 27 89 94 15 2.40 0.83
Berlin 72 44 90 19 1.30 0.63
BMI 34 79 91 15 1.50 0.80
Large neck 20 100 100 16 >10 0.80
AHI Z15 events/h
ESS 21 71 47 42 0.73 1.11
Berlin 74 34 57 52 1.12 0.77
BMI 37 72 61 49 1.30 0.90
Large neck 26 94 83 52 4.21 0.79
AHI, apnea–hypopnea index; ESS, Epworth Sleepiness Scale; LR, likelihood ratio; NPV, negative predictive value; OSA, obstructive sleep apnea; PPV, positive predictive
value; large neck, neck circumference Z43.2 or 40.6 cm, for men and women, respectively.
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Our study has several potential limitations. Our patients
were overweight but not overtly obese, therefore the
prevalence of OSA in populations with higher obesity
prevalence rates is likely higher. The number of technical
problems related to PM was relatively small (5.3%) and in
the same range of previous studies (3–18%) [25]. The low
number of PM technical problems may be due to the fact
that the studies were performed on the ward and scored by
an experienced sleep technician and interpreted by a
qualified sleep medicine physician; however, it is possible
that the failure rate of PM when performed at home would
be greater. Therefore, our data support only the use of PM
in the in-patient setting, not at home. In contrast, we have
recently reported similar technical performance using the
same device at home in patients with hypertrophic
cardiomyopathy [8]. Despite the presence of low ejection
fraction in a significant proportion of our patients, we found
a low prevalence of central sleep apnea. Therefore, our
study does not fully allow elucidation of the use of PM in
the setting of central sleep apnea. However, Quintana-
Gallego et al. [43] have earlier validated the use of PM in
patients with stable congestive heart failure in whom a
significant proportion had central sleep apnea. In our study,
patients who had a diagnosis of OSA were referred for
follow-up in the sleep clinic for specific evaluation and
treatment after surgery. Therefore, further studies are
necessary to clarify the importance of OSA detection and
treatment in patients with established CAD in the pre- and
postoperative period of CABG.
In summary, this study showed that OSA is extremely
common among patients referred to CABG and that
clinical characteristics are not adequate signs to identify
OSA in this population. We further showed that type 3
PM is useful tool for the diagnosis of OSA in consecutive
patients with severe CAD evaluated for CABG. Further
studies are needed to determine the best management
and the impact of treatment of OSA in patients with
CAD evaluated for CABG.
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